Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from cyclosporine to tacrolimus modified release in stable kidney transplant recipients
2006-004606-97Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tacrolimus, sponsored by Astellas Pharma. Primary endpoint: Change in creatinine clearance from baseline to week 24 by cyclosporine-related side-effect subgroup. Started Jan 2007; status: completed.
02
Drugs
tacrolimus
Beyond the preview
Go deeper on 2006-004606-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004606-97.